MET and hepatocellular carcinoma: Cabozantinib, a tyrosine kinase inhibitor targeting Vascular Endothelial Growth Factor-Rezeptor 2, AXL, and MET in patients with advanced HCC who progressed on sorafenib was evaluated in the phase III CELESTIAL trial.